Skip to main content
SpringerLink
Log in

Gestagens in the management of prostatic carcinoma

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Two different hormonal gestagens, cyproterone acetate and norethisterone, were studied in prostatic carcinoma, for the greatest part in advanced cases. Cyproterone acetate was administered to 80, norethisterone to 38 unselected patients. The period of study extended over 2 years or more. The mechanism of action of gestagens and the role of the hormone receptors are discussed. The significance of serial measurements of plasma testosterone by providing a monitor of hormonal therapy is emphasized. The relevant literature is reviewed. The value of gestagens as an alternative to the traditional hormone therapy of prostatic carcinoma is pointed out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anglade, J. P.: Norethisterone acetate and endometriosis.Therapia, 27, 779 (1972).

    Google Scholar 

  2. Bashirelani, N., Young, J. D.: Specific binding protein for 17-beta-estradiol in prostate with adenocarcinoma.Urology, 8, 553 (1966).

    Google Scholar 

  3. Bracci, U.: Antiandrogens in the treatment of prostatic cancer.Eur. Urol., 5, 303 (1979).

    PubMed  Google Scholar 

  4. Bracci, U., Di Silverio, F.: Il cancro della prostata: nostri attuali orientamenti terapeutici.Prog. Med., 29, 779 (1973).

    Google Scholar 

  5. Bracci, U.: Intérêt de la cyproterone dans les métastases du carcinoma de la prostate.J. Urol. Néphrol. (Paris),79, 405 (1979).

    Google Scholar 

  6. Bracci, U., Di Silverio, F.: Role of Cyproterone acetate in Urology. In: L. Martini, M. Motta (eds): Androgens and Antiandrogens. Raven Press, New York 1977.

    Google Scholar 

  7. Bracci, U., Di Silverio, F., Sciarra, F., Sorcini, G., Piro, C., Snatoro, F.: Hormonal pattern in prostatic carcinoma following orchidectomy: 5-year follow-up.Br. J. Urol., 49, 161 (1977).

    PubMed  Google Scholar 

  8. Catalona, W. J., Scott, W. W.: Carcinoma of the prostate: a review.J. Urol., 119, 1 (1978).

    PubMed  Google Scholar 

  9. Collins, W. P., Koullapis, E. N., Ferguson, K. M., Visvas, S., Sharpler, J., Sommervile, I. F.: Effects of norethisterone on pituitary and ovarian function.Acta Endocrinol. (Copenh.),75, 357 (1974).

    Google Scholar 

  10. Ekman, P., Snochowski, M., Dahlberg, E., Gustafsson, J. A.: Steroid receptors in metastatic carcinoma of the human prostate.Eur. J. Cancer, 15, 257 (1979).

    PubMed  Google Scholar 

  11. Fang, S., Anderson, K. M., Liac, S.: Receptor proteins in selective retention of 17-beta-hydroxy-5-alpha-androstan-3-one by rat ventral prostate in vivo and in vitro.J. Biol. Chem., 244, 6584 (1969).

    PubMed  Google Scholar 

  12. Geller, J., Bora, R., Roberts, T., Newman, H., Lin, A., Silva, R.: Treatment of benign prostatic hypertrophy with 17-alpha-hydroxyprogesterone caproate.JAMA, 193, 121 (1965).

    PubMed  Google Scholar 

  13. Geller, J., Fruchtman, B., Meyer, C., Newman, H.: Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.J. Clin. Endocrinol. Metab., 27, 556 (1967).

    PubMed  Google Scholar 

  14. Geller, J., Fruchtman, B., Newman, H., Roberts, T., Silva, R.: Effect of progestational agents on carcinoma of the prostate.Cancer Treat. Rep., 51, 41 (1967).

    Google Scholar 

  15. Gerhards, E., Hecker, W., Hitze, H., Nieuweber, B., Bellmann, O.: The metabolism of norethisterone and of DL and D-norgestrol in man.Acta Endocrinol. (Copenh.),68, 219 (1971).

    Google Scholar 

  16. Ghanadian, R., Puach, C. M., O'Donoghues, E. P. N.: Serum testosterone and dihydrotestosterone in carcinoma of the prostate.Br. J. Cancer, 39, 696 (1979).

    PubMed  Google Scholar 

  17. Gimes, R., Csömör, S., Német, J.: Observations with gestagens.Magy. Nőorv. Lapja, 39, 370 (1976).

    Google Scholar 

  18. Gustafsson, J. A., Ekman, P., Snochowski, M.: Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer.Cancer Res., 38, 4345 (1978).

    PubMed  Google Scholar 

  19. Hardy, J.: Essai de traitement du cancer prostatique par les oestrogènes asseriés à acétate de cyprotérone.Acta Urol. Belg., 48, 110 (1980).

    PubMed  Google Scholar 

  20. Hutschenreiter, G., Sinterhaus, K., Altwein, J. E.: Kinetics of3H-testosterone and3H-dihydrosterone metabolism in patients with benign prostatic hypertrophy, effect of cyproterone acetate.Eur. Urol., 3, 100 (1977).

    PubMed  Google Scholar 

  21. Karr, J. P., Sandberg, A. A.: Steroid receptors and prostatic cancer. Ed.: G. P. Murphy. Littleton, PSG Publishing Co., Massachusetts 1979, pp. 49–74.

    Google Scholar 

  22. Kent, J. R., Bischoff, A. J., Arduino, L. J., Mellinger, G. T., Byar, D. P., Hill, M., Kozbur, X.: Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma.J. Urol., 109, 858 (1979).

    Google Scholar 

  23. Kisbenedek, L., Szendi, L., Balogh, F., Bodrogi, L., Fehér, T.: Significance of RIA-assay of plasma testosterone in the therapy of prostatic cancer. (Lecture).

  24. Klosterhalfen, H.: Das Prostatakarzinom. Epidemiologie, Klassifizierung, Diagnostik, Therapie.Med. Klin., 72, 376 (1977).

    PubMed  Google Scholar 

  25. Markowitz, M., Veenema, R. J., Gingerhut, B., Nehme-Haily, D., Sommers, S. C.: Cyproterone acetate (SH 714), effect on histology and nucleic acid synthesis in the testes of patients with prostatic carcinoma: a preliminary report.Invest. Urol., 6, 638 (1969).

    PubMed  Google Scholar 

  26. Markland, F. S. Jr., Lee, I.: Characterization and comparison of the estrogen and androgen receptors from the R-3327 rat prostatic carcinoma.J. Steroid Biochem., 10, 13 (1979).

    PubMed  Google Scholar 

  27. Mauermayer, W.: Experiences with cyproterone acetate. Internat. Symposium, Berlin 1969.

  28. Mellin, P.: Experiences with cyproterone acetate. Internat. Symposium, Berlin 1969.

  29. Menon, M., Tananin, C. E., McLoughen, M. G., Walsh, P. C.: Androgen receptors in human prostatic tissue: a review.Cancer Treat. Rep., 61, 265 (1977).

    PubMed  Google Scholar 

  30. Mobbs, B. G., Johnson, E. E., Connoly, J. G., Clark, A. F.: Evaluation of the use of cyproterone acetate competition to distinguish between high-affinity binding of3H-dihydrotestosterone to human prostate cytosol receptors and sex-hormone-binding globulin.J. Steroid Biochem., 8, 943 (1977).

    PubMed  Google Scholar 

  31. Mobbs, B. G., Johnson, E. E., Connoly, J. G., Clark, A. F.: Androgen receptor assay in human benign and malignant prostatic tumor cytosol using protamine sulphate precipitation:J. Steroid Biochem., 9, 289 (1978).

    PubMed  Google Scholar 

  32. Nagamatsu, G. R.: Use of cyproterone acetate in stages III and IV Internat. Symposium, Berlin 1969.

  33. Neri, R., Casmer, C., Zeman, W. V., Fiedler, F., Tabacknick, I. A.: Effect of an antiandrogen (SH-714) on canine prostatic hyperplasia.Endocrinology, 82, 311 (1968).

    Google Scholar 

  34. Neuman, F.: Chemie, Biochemie und pharmakologische Grundlagen der Antiandrogene.Dtsch. Ärzteblatt, 75, 1933 (1978).

    Google Scholar 

  35. Neuman, F.: Klinik der Antiandrogene.Dtsch. Ärzteblatt, 75, 1691 (1978).

    Google Scholar 

  36. Pertschuk, L. P., Zava, D. T., Gastjens, E.: Detection of androgen and estrogen receptors in human prostatic carcinoma and hyperplasia by fluorescence microscopy.Commun. Chem. Pathol. Pharmacol., 22, 437 (1978).

    Google Scholar 

  37. Reed, M. J., Fortherby, K., Pech, H. E., Gordon, Y.: Localization of norethisterone in the reproductive tract of women.J. Endocrinol., 59, 569 (1973).

    PubMed  Google Scholar 

  38. Rosen, V., Jung, I., Baulieu, E. E., Roberl, P.: Androgen-binding proteins in human benign prostatic hypertrophy.J. Clin. Endocrinol. Metab., 41, 761 (1975).

    PubMed  Google Scholar 

  39. Scott, W. W., Schirmer, H. K. A.: A new oral progestational steroid effective in treating prostatic cancer.Trans. Am. Assoc. Genitourin. Surg., 58, 54 (1966).

    PubMed  Google Scholar 

  40. Scott, W. W., Wade, J. C.: Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate.J. Urol., 101, 81 (1969).

    PubMed  Google Scholar 

  41. Schearer, R. J., Hendry, W. F., Sommerville, I. F., Ferguson, J. D.: Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer.Br. J. Urol., 45, 667 (1973).

    Google Scholar 

  42. Sidh, S. M., Young, J. Jr., Kami, S. A.: Adenocarcinoma of prostate: Role of 17-betaestradiol and 5-alpha-dihydrotestosterone binding.Urology, 13, 597 (1979).

    PubMed  Google Scholar 

  43. Smith, R. B., Walch, P. C., Goodwin, W. E.: Cyproterone acetate in the treatment of advanced carcinoma of the prostate.J. Urol., 110, 106 (1973).

    PubMed  Google Scholar 

  44. Snochowski, M., Pousette, A., Ekman, P., Bression, D., Anderson, L., Hogberg, B., Gustafsson, J. A.: Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma.J. Clin. Endocrinol. Metab., 45, 920 (1977).

    PubMed  Google Scholar 

  45. Sorcini, G., Sciarra, F., Di Silverio, F.: Effect of cyproterone on plasma androgen in normal males.Folia Endocrinol. (Roma),3, 278 (1969)

    Google Scholar 

  46. Szendrői, Z.: Cyproterone acetate in the therapy of prostatic cancer.Urol. Nephrol. Szle., 4, 213 (1981).

    Google Scholar 

  47. Walsh, P. G., Koremen, S. G.: Mechanism of androgenic action. I. Effect of specific intracellular inhibitors.J. Urol., 105, 850 (1971).

    PubMed  Google Scholar 

  48. Tenhaeff, D., Petry, R., Senge, Th., Rauch-Stromann, J. G.: 3-month contraception with norethisterone. Clinical and biochemical studies.Med. Welt, 40, 1551 (1971).

    PubMed  Google Scholar 

  49. Tenhaeff, D., Feldmann, H. U., Rupek, R.: Contraception with two dosage mestranonorethisterone combinations.Fortschr. Med., [Suppl. 90], 479 (1972).

    Google Scholar 

  50. Wein, A. J., Murphy, J. J.: Experience in the treatment of prostatic carcinoma with cyproterone acetate.J. Urol., 109, 68 (1973).

    PubMed  Google Scholar 

  51. Young, H. H., Kent, J. R.: Plasma testosterone levels in patients with prostatic carcinoma before and after treatment.J. Urol., 99, 788 (1968).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, County Hospital, Székesfehérvár, Hungary

    Z. Szendrői

Authors
  1. Z. Szendrői
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szendrői, Z. Gestagens in the management of prostatic carcinoma. International Urology and Nephrology 16, 327–335 (1984). https://doi.org/10.1007/BF02081869

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02081869

Keywords

Search

Navigation